In 2022, we made important progress in the STOP clinical trial to test the efficacy of a fixed-dose combination of ivermectin and albendazole for the treatment of soil-transmitted helminths (1). Phases I and II of the trial have been completed and recruitment for phase III will be completed in March 2023.
On Chagas disease, we estimate that more than 50,000 people in Spain live with the disease, but many women of childbearing age remain undiagnosed and untreated (2). With this in mind, we launched the ChagasLAMP consortium to validate new, faster and more effective diagnostic methods to interrupt mother-to-child transmission of the disease. We also started a research line that will apply computational methods for the discovery of new drugs for treating the disease.
Regarding migrant health, we demonstrated the usefulness of an electronic registry system to identify and address the health needs of this vulnerable population (3) and launched a new project to improve data collection and health surveillance of migrant populations in North Africa and the Middle East (5). We completed the CRIBMI project, which tested a clinical decision support system for multi-disease screening in primary care.